| Dr Jason Okulicz, MD | |
|
Brooke Army Medical Center, 3551 Roger Brooke Drive, Fort Sam Houston, TX 78234 | |
| (210) 916-5554 | |
| Not Available |
| Full Name | Dr Jason Okulicz |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Infectious Disease |
| Location | Brooke Army Medical Center, Fort Sam Houston, Texas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427082874 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | 0101236197 (Virginia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jason Okulicz, MD Brooke Army Medical Center, 3551 Roger Brooke Drive, Fort Sam Houston, TX 78234 Ph: () - | Dr Jason Okulicz, MD Brooke Army Medical Center, 3551 Roger Brooke Drive, Fort Sam Houston, TX 78234 Ph: (210) 916-5554 |
News Archive
Results from laboratory experiments and mouse studies suggest that small doses of drugs from a specific class of approved cancer medications called topoisomerase 1 (top1) inhibitors may protect against the overwhelming immune response to infection that sometimes leads to sepsis, a bacterial condition that kills as many as 500,000 people in the United States each year.
A new national survey released today by Working Mother Media and Pfizer on the impact of menopausal symptoms on women in the workplace finds that managing menopausal symptoms in their work life is extremely or somewhat difficult for nearly half (48 percent) of working women ages 45-65 who have experienced these symptoms in the past year.
Cephalon, Inc. (Nasdaq: CEPH) today announced receipt of a Paragraph IV Certification Notice Letter on October 20, 2009 regarding an Abbreviated New Drug Application (ANDA) submitted to the U.S. Food and Drug Administration (FDA) by Teva Pharmaceuticals USA, Inc. requesting approval to market and sell a generic version of the 50 mg, 100 mg, 150 mg, 200 mg and 250 mg strengths of NUVIGIL® (armodafinil) Tablets [C-IV].
Restoring testosterone production in men may be as effective as replacing it, without compromising their fertility. Two phase III clinical trials show that a drug that restores the body's natural production of testosterone has no negative effect on a man's sperm count while a topical testosterone gel causes a significant drop.
› Verified 7 days ago
Dr. Rosemary Chacko, MD Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 3551 Roger Brooke Dr, Fort Sam Houston, TX 78234 Phone: 210-539-9582 Fax: 210-916-5102 | |
Andre John Ognibene, MD Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 3851 Roger Brooke Dr, Mche-qd (creds), Fort Sam Houston, TX 78234 Phone: 210-916-5993 | |
Christopher Paul Irwin, M.D Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 3551 Roger Brooke Dr, Fort Sam Houston, TX 78234 Phone: 916-210-2338 | |
Gilbert Patrick Ancira, MD Infectious Disease Medicare: Medicare Enrolled Practice Location: 3551 Roger Brooke Dr, Fort Sam Houston, TX 78234 Phone: 210-916-4808 | |
Sarah Dang, MD Infectious Disease Medicare: Medicare Enrolled Practice Location: 3551 Roger Brooke Dr, Fort Sam Houston, TX 78234 Phone: 210-539-7074 | |
Dr. Raul A. Rivera, MD Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 3851 Roger Brooke Dr, Brooke Army Medical Center Mche-qd (credentials), Fort Sam Houston, TX 78234 Phone: 210-916-2460 | |
Dr. Leslie Ann Wood, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 3551 Rogers Brooke Drive, San Antonio Military Medical Center, Fort Sam Houston, TX 78234 Phone: 210-916-9844 |